Injection of allergen-antibody complexes is an effective treatment of atopic dermatitis.

Dermatologica Pub Date : 1991-01-01 DOI:10.1159/000247754
B P Leroy, J M Lachapelle, M M Somville, M G Jacquemin, J M Saint-Remy
{"title":"Injection of allergen-antibody complexes is an effective treatment of atopic dermatitis.","authors":"B P Leroy,&nbsp;J M Lachapelle,&nbsp;M M Somville,&nbsp;M G Jacquemin,&nbsp;J M Saint-Remy","doi":"10.1159/000247754","DOIUrl":null,"url":null,"abstract":"<p><p>Atopic dermatitis (AD) can be exacerbated by contact with airborne allergens, amongst which Dermatophagoides pteronyssinus (Dpt) appears to be potentially important. Specific IgE antibodies towards Dpt are often found in AD, and it can therefore be speculated that suppression of the production of anti-Dpt IgE might result in a significant clinical improvement. Complexes of antigen and specific antibodies have been shown to suppress the production of antibody in other systems; we report here the evaluation in an open trial of the capacity of such complexes to improve symptoms of AD. Ten adult patients were enrolled in this study. In addition to satisfying the criteria of AD, they all suffered from a severe disease (more than 20% of the body surface involved) that had been stable for at least the last 2 years. The patients had high titers of total IgE antibodies and specific anti-Dpt antibodies. Allergen-antibody complexes were prepared from Dpt allergens and an excess of autologous specific anti-Dpt antibodies obtained by immunoadsorption. The patients received regular injections of these complexes throughout 1 year, during which clinical parameters of disease intensity, percentage of body surface affected and intensity of pruritus were regularly monitored. A significant clinical improvement was obtained after 3-4 months of therapy and was maintained through the 9th month. After 1 year of treatment, 2 patients were completely free of disease, 4 had residual lesions which continued to improve and 4 patients had a partial recurrence of dermatitis.(ABSTRACT TRUNCATED AT 250 WORDS)</p>","PeriodicalId":11117,"journal":{"name":"Dermatologica","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1991-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000247754","citationCount":"24","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000247754","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 24

Abstract

Atopic dermatitis (AD) can be exacerbated by contact with airborne allergens, amongst which Dermatophagoides pteronyssinus (Dpt) appears to be potentially important. Specific IgE antibodies towards Dpt are often found in AD, and it can therefore be speculated that suppression of the production of anti-Dpt IgE might result in a significant clinical improvement. Complexes of antigen and specific antibodies have been shown to suppress the production of antibody in other systems; we report here the evaluation in an open trial of the capacity of such complexes to improve symptoms of AD. Ten adult patients were enrolled in this study. In addition to satisfying the criteria of AD, they all suffered from a severe disease (more than 20% of the body surface involved) that had been stable for at least the last 2 years. The patients had high titers of total IgE antibodies and specific anti-Dpt antibodies. Allergen-antibody complexes were prepared from Dpt allergens and an excess of autologous specific anti-Dpt antibodies obtained by immunoadsorption. The patients received regular injections of these complexes throughout 1 year, during which clinical parameters of disease intensity, percentage of body surface affected and intensity of pruritus were regularly monitored. A significant clinical improvement was obtained after 3-4 months of therapy and was maintained through the 9th month. After 1 year of treatment, 2 patients were completely free of disease, 4 had residual lesions which continued to improve and 4 patients had a partial recurrence of dermatitis.(ABSTRACT TRUNCATED AT 250 WORDS)

注射过敏原抗体复合物是治疗特应性皮炎的有效方法。
特应性皮炎(AD)可因接触空气中的过敏原而加重,其中翼状窦性皮炎(Dpt)似乎具有潜在的重要性。在AD中经常发现针对Dpt的特异性IgE抗体,因此可以推测抑制抗Dpt IgE的产生可能会导致显著的临床改善。抗原和特异性抗体的复合物已被证明可以抑制其他系统中抗体的产生;我们在此报告一项公开试验中对此类复合物改善AD症状的能力的评估。10名成年患者参加了这项研究。除了符合AD的标准外,他们都患有严重的疾病(超过20%的体表受累),并且至少在过去2年内病情稳定。患者总IgE抗体和特异性抗dpt抗体滴度均较高。过敏原-抗体复合物由Dpt过敏原和免疫吸附获得的过量的自体特异性抗Dpt抗体制备。患者在1年内定期注射这些复合物,在此期间定期监测疾病强度、体表受影响百分比和瘙痒强度的临床参数。治疗3-4个月后获得显著的临床改善,并维持到第9个月。治疗1年后,2例完全痊愈,4例皮炎残余病变持续改善,4例皮炎部分复发。(摘要删节250字)
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信